Lisanti Capital Growth’s ChemoCentryx, Inc. CCXI Stock Holding History

Lisanti Capital Growth’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-184,946	Closed	-$4.58M	–	142
2022 Q2	$4.58M	Sell	184,946 -136,623	-42%	-$3.01M	0.62%	70
2022 Q1	$8.06M	Buy	321,569 +90,534	+39%	+$2.54M	0.91%	45
2021 Q4	$8.41M	Buy	+231,035	New	+$8.11M	1.22%	23

Other funds holding CCXI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Lisanti Capital Growth's CCXI Position: Q3 2022 in Review

Lisanti Capital Growth sold out of ChemoCentryx, Inc. (CCXI) in Q3 2022, closing a stake of 184,946 shares — an estimated $4.58M sold.

Lisanti Capital Growth first reported a position in CCXI in Q4 2021 and held it in 3 quarters. The position peaked at $8.41M in Q4 2021. 217 funds tracked by Wall St. Rank hold CCXI as of Q3 2022.

Lisanti Capital Growth reported no remaining ChemoCentryx, Inc. position as of Q3 2022 after selling out during the quarter.
Lisanti Capital Growth sold 184,946 ChemoCentryx, Inc. shares in Q3 2022, an estimated $4.58M.
Lisanti Capital Growth first reported a position in ChemoCentryx, Inc. in Q4 2021 and held it in 3 quarters.
Lisanti Capital Growth's ChemoCentryx, Inc. position peaked at $8.41M in Q4 2021.
217 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2022.

Based on Lisanti Capital Growth's 13F filing for Q3 2022, filed 2 Nov 2022.